



Docket No.: 31894-202098
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Zemel et al.

Art Unit: 1616

Application No: 10/827,296

Examiner: E. J. Webman

Confirmation No: 2568

Filed: April 20, 2004

Atty. Docket No: 31894-202098

For: METHOD OF REDUCING RISK OF A
WEIGHT-RELATED HEALTH DISEASE

Customer No:

26694
26694

PATENT TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (IDS)

MS AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. Copies of **Documents B1-B4** and **C1-C16** are enclosed.

Document C13 was cited in counterpart Application No. 10/827,353 in an Office Action dated September 18, 2007. Documents C14-C16 were cited in counterpart Application No. 10/066,057 in an Office Action dated November 26, 2007.

03/31/2008 SZWDIE1 00000006 220261 10827296
01 FC:1806 188.00 DA

This Information Disclosure Statement is filed after the mailing date of a Notice of Withdrawal from Issue and before the mailing date of any action that closes prosecution in this application (37 CFR 1.97(c)). A fee of \$180 is enclosed (1.97 (c)(2)). Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patent documents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

We believe that no further fees are required with the submission of this IDS. However, the Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0261, under Order No. 31894-202098.

Dated:

Respectfully submitted,

DC2/913323

By 
Michael A. Gollin

Registration No.: 31,957

Zayd Alathari

Registration No.: 42,256

VENABLE LLP

P.O. Box 34385

Washington, DC 20043-9998

(202) 344-4000

(202) 344-8300 (Fax)

Attorney/Agent For Applicant